Listen
TREMFYA (guselkumab)
Reason for request
Maintenance of the favourable opinion for reimbursement in a limited indication for the treatment of severe chronic forms of adult plaque psoriasis, defined by:
- failure (insufficient response, contraindication or intolerance) of at least two treatments including non-biological systemic treatments and light therapy
- and an extensive form and/or psychosocial impact.
Unfavourable opinion for reimbursement in the other clinical situations.
Clinical Benefit
| Substantial |
The clinical benefit of TREMFYA 100 mg solution for injection in pre-filled syringe remains substantial only in the treatment of adult plaque psoriasis, in patients with severe chronic plaque psoriasis, defined by:
|
| Insufficient |
In other forms, the clinical benefit remains insufficient to justify reimbursement by public funding. |
Clinical Added Value
| minor |
TREMFYA 100 mg (guselkumab) solution for injection provides minor clinical added value (CAV IV) compared to COSENTYX (secukinumab) in the treatment of adult plaque psoriasis, in patients with severe chronic plaque psoriasis, defined by:
|
